Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to -$2.4 million.

  • Iovance Biotherapeutics' Tax Provisions fell 5822.37% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$671000.0, marking a year-over-year increase of 8919.14%. This contributed to the annual value of -$2.8 million for FY2024, which is 1920.0% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Tax Provisions is -$2.4 million, which was down 5822.37% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Tax Provisions peaked at $2.0 million during Q2 2025, and registered a low of -$2.4 million during Q3 2025.
  • In the last 3 years, Iovance Biotherapeutics' Tax Provisions had a median value of -$1.5 million in 2024 and averaged -$862200.0.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 20000.0% in 2024, then soared by 23333.33% in 2025.
  • Quarter analysis of 3 years shows Iovance Biotherapeutics' Tax Provisions stood at -$1.8 million in 2023, then soared by 188.31% to $1.6 million in 2024, then crashed by 252.99% to -$2.4 million in 2025.
  • Its last three reported values are -$2.4 million in Q3 2025, $2.0 million for Q2 2025, and -$1.8 million during Q1 2025.